Article Contents ::
- 1 The Brand Name MOXIFEN Has Generic Salt :: Tamoxifen
- 2 MOXIFEN Is From Company VHB Priced :: Rs. 11.50/18.00
- 3 MOXIFEN have Tamoxifen is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
- 4 Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name MOXIFEN Has Generic Salt :: Tamoxifen
MOXIFEN Is From Company VHB Priced :: Rs. 11.50/18.00
MOXIFEN have Tamoxifen is comes under Sub class Anti Neoplastic Agents of Main Class Anti Neoplastic Agents
Main Medicine Class:: Anti Neoplastic Agents Sub Medicine Class :: Anti Neoplastic Agents
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Tamoxifen | TAB | Rs. 11.50/18.00 | 10-Oct |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10-Oct |
| MOXIFEN | VHB | 10/20;MG | 10-Oct | Rs. 11.50/18.00 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From VHB :: MOXIFEN | Tamoxifen | Anti Neoplastic Agents | Anti Neoplastic Agents |
Indications for Drugs ::
Breast cancer
Drug Dose ::
Adult: PO Breast cancer 20 mg in 1-2 divided doses. Max: 40 mg/day. Reduction of breast cancer incidence in high-risk women 20 mg/day for 5 yr. Anovulatory infertility 20 mg/day on days 2-5 of the menstrual cycle. Max: 80 mg/day. Adult: PO Breast cancer 20 mg in 1-2 divided doses. Max: 40 mg/day. Reduction of breast cancer incidence in high-risk women 20 mg/day for 5 yr. Anovulatory infertility 20 mg/day on days 2-5 of the menstrual cycle. Max: 80 mg/day.
Contraindication ::
Pregnancy and lactation. History of thromboembolic events.
Drug Precautions ::
Perform routine haematological and liver function tests in long-term therapy. Gynaecological monitoring is necessary in women.
Drug Side Effects ::
Hot flushes, oedema, fluid retention, dry skin, vaginal bleeding, vaginal discharge, pruritus vulvae, GI upsets, nausea, dizziness, rashes, blurred vision, loss of acuity, alopecia, increased liver enzymes, hypertriglyceridaemia, uterine fibroids and endometrial hyperplasia. Potentially Fatal: Blood dyscrasias, cholestasis, hepatitis, hypercalcaemia in patients with bone metastasis, thromboembolic events. Increased risk of endometrial cancer and uterine sarcoma.
Pregnancy category ::
4
Drug Mode of Action ::
Tamoxifen, a triphenylethylene derivative, produces a nuclear complex by competitively binding to oestrogen receptors on tumours and other tissue targets thus, decreasing DNA synthesis and inhibiting oestrogen effect. It is only cytostatic rather than cytotoxic due to accumulation of cell in G0 and G1 phases.
Drug Interactions ::
Aminoglutethimide reduces plasma-tamoxifen concentration. Potentially Fatal: Concurrent use increased anticoagulant effect of warfarin; increased risk of thromboembolic events with other cytotoxic drugs.
